The designation will provide Lundbeck with the possibility of rolling reviews and detailed guidance to streamline the drug ...

Recognizing Siegel’s importance as an employee and a respected figure among Israeli psychiatrists, Lundbeck Global took ...

The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

Lundbeck focuses on central nervous system drugs, including antidepressants, antipsychotics, and antiepileptic products. While incremental innovations and label expansions have helped Lundbeck ...

Amlenetug received Orphan Drug Designation (ODD) from the US FDA in April 2024, the EMA in May 2021 and SAKIGAKE designation ...

Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster. The Danish drugmaker has ...

Denmark’s Lundbeck is bringing a third potential drug for Parkinson’s disease to the clinic – a human antibody that the company hopes will tackle the underlying cause of the condition.

Lundbeck’s total revenue grew by +14% at constant exchange rates (CER) and 11% in kroner terms to 22,004 million kroner ...

H. Lundbeck A/S (Lundbeck) announces that, after 12 years of dedicated service on Lundbeck’s Board of Directors, Lars Søren Rasmussen has informed his decision not to seek re-election at the Annual ...

Bexicaserin achieved an overall median seizure reduction of 59.3 percent in countable motor seizures over a 12-month open-label extension (OLE) treatment period. The treatment with bexicaserin ...

Key highlights Lundbeck's total revenue grew by +14% CER[1] (+11% DKK) to DKK 22,004 million in 2024, with all regions contributing to growth United States: DKK 11,325 million (+16% CER; +15% DKK) Eur ...

Lundbeck’s potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the ...